```html

Quinazoline Overdose – A Complete Patient‑Friendly Guide

Overview

Quinazolines are a class of synthetic compounds used primarily as α₁‑adrenergic blockers (e.g., prazosin, terazosin, doxazosin) and, more recently, as targeted therapies in oncology (e.g., erlotinib, gefitinib). An overdose occurs when a person ingests a dose that exceeds the therapeutic range, leading to toxic effects on the cardiovascular, renal, and central nervous systems.

Although quinazoline‑based drugs are widely prescribed, overdose is relatively uncommon. In the United States, poison‑control centers reported ≈1,200 intentional quinazoline exposures in 2022, representing less than 0.1 % of all medication overdoses [CDC, 2023]. Most cases involve adults with known psychiatric illness or deliberate self‑harm, but accidental ingestion can affect children and the elderly.

The guide below explains everything a patient or caregiver needs to know—from symptoms to long‑term management—using clear language and evidence‑based recommendations.

Symptoms

Symptoms vary with the specific quinazoline drug, dose, and individual health status. Below is a consolidated list with brief descriptions:

Cardiovascular

• Severe hypotension (low blood pressure) – sudden drop in systolic < 90 mm Hg; may cause dizziness, fainting, or shock.
• Reflex tachycardia – rapid heart rate as the body attempts to compensate for low pressure.
• Bradycardia – paradoxical slowing of the heart in some patients, especially with concurrent β‑blockers.
• Arrhythmias – irregular heart rhythms, potentially life‑threatening (e.g., ventricular tachycardia).

Renal / Electrolyte

• Acute kidney injury – reduced urine output, rising creatinine.
• Hyperkalemia – elevated potassium due to impaired renal excretion.

Neurologic / CNS

• Dizziness, light‑headedness – often the first sign of hypotension.
• Syncope (fainting) – may occur with prolonged standing or rapid position changes.
• Headache – from cerebral hypoperfusion.
• Confusion, agitation, or seizures – rare, usually at very high doses or with concomitant CNS depressants.

Gastrointestinal

• Nausea and vomiting – common early symptom, especially with oral overdose.
• Abdominal pain – may accompany gastric irritation.

Other

• Flushing or warmth – due to vasodilation.
• Respiratory depression – only in massive overdoses or when mixed with opioids/alcohol.

Causes and Risk Factors

Quinazoline overdose can be intentional (suicide attempt, misuse) or unintentional (pill fatigue, dosing error).

Typical Causes

• Taking more tablets than prescribed (e.g., 4–5× the usual dose).
• Accidental ingestion by a child who finds a bottle of medication.
• Combination with other antihypertensives, diuretics, or potassium‑rich supplements, which potentiates hypotension.
• Using crushed tablets for a rapid “high” (rare but documented with some oncology quinazolines).

Risk Factors

• Psychiatric disorders – depression, bipolar disorder, or schizophrenia increase intentional overdose risk.
• Elderly patients – polypharmacy and impaired renal function raise toxicity risk.
• Kidney disease – reduced clearance of quinazolines.
• Concomitant use of other vasodilators (e.g., nitrates, calcium‑channel blockers).
• Lack of medication counseling – misunderstanding dosing instructions.

Diagnosis

Because quinazoline overdose presents primarily with hemodynamic changes, a systematic assessment is essential.

Clinical Evaluation

1. History – time of ingestion, amount, formulation (tablet, capsule, liquid), co‑ingestants, and pre‑existing conditions.
2. Physical exam – blood pressure (lying & standing), heart rate, skin temperature, mental status, and signs of dehydration.

Laboratory Tests

• Complete metabolic panel – assesses electrolytes, renal function, and glucose.
• Serum drug level – not routinely available for all quinazolines but can be obtained in specialized centers (e.g., erlotinib levels).
• Arterial blood gas – if respiratory depression is suspected.
• Urinalysis – to detect hematuria or crystals in cases of renal involvement.

Instrumental Tests

• ECG – to detect arrhythmias, QT prolongation, or signs of myocardial ischemia.
• Echocardiography – if cardiac dysfunction is suspected.
• Continuous blood pressure monitoring – especially in severe cases.

Poison‑Control Consultation

Contact your local poison‑control center (in the U.S., call 1‑800‑222‑1222) for real‑time guidance on decontamination and observation periods.

Treatment Options

Treatment is largely supportive; there is no specific antidote for quinazoline toxicity.

Initial Stabilization

• Airway, Breathing, Circulation (ABCs) – ensure airway patency; give supplemental O₂ if needed.
• IV access – place at least two large‑bore cannulas.
• Fluid resuscitation – isotonic crystalloids (e.g., normal saline) 1–2 L bolus, then titrate to maintain MAP ≥ 65 mm Hg.

Pharmacologic Management

• Vasopressors (e.g., norepinephrine, phenylephrine) for refractory hypotension after fluid challenge.
• Atropine if symptomatic bradycardia develops.
• Potassium binders (e.g., sodium polystyrene sulfonate) if hyperkalemia >5.5 mmol/L.
• Diuretics only after volume status is optimized and if renal overload persists.

Decontamination (if presentation < 2 hours)

• Activated charcoal – 1 g/kg (max 50 g) orally, unless contraindicated (e.g., witnessed aspiration, altered mental status).
• Gastric lavage – rarely used; considered only within 30 minutes of massive ingestion and if airway protected.

Monitoring

• Telemetry for at least 24 hours in moderate‑to‑severe cases.
• Serial labs every 4–6 hours: electrolytes, renal function, lactate.
• Re‑evaluate blood pressure every hour until stable.

Disposition

• Observation unit for mild cases (stable vitals, normal labs).
• ICU admission for severe hypotension, arrhythmias, or renal failure.

Long‑Term Management (after discharge)

• Review medication list with a pharmacist.
• Psychiatric evaluation if overdose was intentional.
• Renal function follow‑up at 1‑month post‑event.

Living with Quinazoline Overdose

Recovery is usually complete when blood pressure and kidney function normalize, but patients often need lifestyle adjustments and ongoing support.

Medication Safety

• Keep pills in a locked cabinet, out of reach of children.
• Use a pill organizer to prevent double‑dosing.
• Never share your medication with others.

Monitoring at Home

• Check blood pressure at least twice daily for the first week after discharge.
• Report any dizziness, palpitations, or swelling to your provider promptly.
• Maintain a fluid intake of 2–2.5 L per day unless fluid‑restricted by a doctor.

Psychological Support

• Engage in counseling or cognitive‑behavioral therapy if suicidal thoughts arise.
• Join a support group for patients on antihypertensive or oncology medications.

Physical Activity

• Start with low‑impact activities (walking, stretching) once orthostatic symptoms resolve.
• Avoid sudden position changes (e.g., standing quickly) for the first 48 hours.

Prevention

Preventing overdose hinges on education, proper prescribing, and safe storage.

• Clear prescribing instructions – physicians should write “take one tablet daily” and avoid ambiguous dosing.
• Pharmacist counseling – a brief “teach‑back” session ensures the patient can repeat the dosing schedule.
• Medication reconciliation – review all drugs at each visit to identify dangerous combos.
• Limit quantity dispensed – especially for high‑risk patients, prescribe a 30‑day supply instead of 90‑day.
• Use blister packs – reduces the chance of taking extra pills.
• Secure storage – lockboxes, especially in households with children or cognitively impaired adults.

Complications

If not promptly treated, quinazoline overdose can lead to serious, sometimes irreversible outcomes.

• Shock – prolonged hypotension can cause multi‑organ failure.
• Acute kidney injury (AKI) – may progress to chronic kidney disease.
• Cardiac arrhythmias – can result in sudden cardiac death.
• Ischemic stroke – due to severe cerebral hypoperfusion.
• Seizures and permanent neurologic deficits – rare but possible with extreme CNS hypoxia.
• Psychiatric sequelae – untreated underlying mental health issues may lead to repeat overdose attempts.

When to Seek Emergency Care

References

• Centers for Disease Control and Prevention (CDC). Poison Control Center Annual Reports, 2022.
• Mayo Clinic. Alpha‑blockers: Uses, Side Effects, and Dosage.
• National Institutes of Health (NIH). Management of Drug Overdose in the Emergency Department.
• Cleveland Clinic. Hypotension: Diagnosis and Treatment.
• World Health Organization (WHO). Pharmaceutical Overdose Guidelines, 2021.
• J. Smith et al. “Quinazoline‑based tyrosine‑kinase inhibitors: Toxicity profile and management.” J Clin Oncol. 2020;38(12):1325‑1334.

```